JP2022532850A5 - - Google Patents

Info

Publication number
JP2022532850A5
JP2022532850A5 JP2021563175A JP2021563175A JP2022532850A5 JP 2022532850 A5 JP2022532850 A5 JP 2022532850A5 JP 2021563175 A JP2021563175 A JP 2021563175A JP 2021563175 A JP2021563175 A JP 2021563175A JP 2022532850 A5 JP2022532850 A5 JP 2022532850A5
Authority
JP
Japan
Prior art keywords
pyridine
pyrrolo
tetrahydro
methoxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563175A
Other languages
English (en)
Japanese (ja)
Other versions
JP7641913B2 (ja
JP2022532850A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/061176 external-priority patent/WO2020216781A1/en
Publication of JP2022532850A publication Critical patent/JP2022532850A/ja
Publication of JP2022532850A5 publication Critical patent/JP2022532850A5/ja
Application granted granted Critical
Publication of JP7641913B2 publication Critical patent/JP7641913B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563175A 2019-04-24 2020-04-22 ４ｈ－ピロロ［３，２－ｃ］ピリジン－４－オン化合物 Active JP7641913B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962838051P 2019-04-24 2019-04-24
US62/838,051 2019-04-24
US201962940036P 2019-11-25 2019-11-25
US62/940,036 2019-11-25
PCT/EP2020/061176 WO2020216781A1 (en) 2019-04-24 2020-04-22 4h-pyrrolo[3,2-c]pyridin-4-one compounds

Publications (3)

Publication Number Publication Date
JP2022532850A JP2022532850A (ja) 2022-07-20
JP2022532850A5 true JP2022532850A5 (https=) 2023-04-14
JP7641913B2 JP7641913B2 (ja) 2025-03-07

Family

ID=70456765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563175A Active JP7641913B2 (ja) 2019-04-24 2020-04-22 ４ｈ－ピロロ［３，２－ｃ］ピリジン－４－オン化合物

Country Status (26)

Country Link
US (2) US20220298157A1 (https=)
EP (1) EP3959211B1 (https=)
JP (1) JP7641913B2 (https=)
KR (1) KR102915019B1 (https=)
CN (3) CN114127064B (https=)
AU (1) AU2020262221B2 (https=)
BR (1) BR112021019998B1 (https=)
CA (1) CA3137218A1 (https=)
CL (1) CL2021002770A1 (https=)
CO (1) CO2021014022A2 (https=)
CR (1) CR20210530A (https=)
DK (1) DK3959211T3 (https=)
DO (1) DOP2021000216A (https=)
EC (1) ECSP21077614A (https=)
FI (1) FI3959211T3 (https=)
GE (2) GEP20247648B (https=)
IL (1) IL287390B2 (https=)
JO (1) JOP20210285A1 (https=)
MA (1) MA55751A (https=)
MX (1) MX2021012987A (https=)
PE (1) PE20220254A1 (https=)
PH (1) PH12021552693A1 (https=)
SG (1) SG11202111304UA (https=)
TW (1) TWI849114B (https=)
UA (1) UA130453C2 (https=)
WO (1) WO2020216781A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700904B1 (en) 2017-10-24 2023-07-19 Bayer AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US12403135B2 (en) 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CN115836070B (zh) * 2020-08-10 2024-08-09 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
KR20230094197A (ko) * 2020-09-23 2023-06-27 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료에 유용한 피롤로[3,2-c]피리딘-4-온 유도체들
WO2022094271A1 (en) * 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
EP4244225A1 (en) * 2020-11-11 2023-09-20 Bayer Aktiengesellschaft N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN118019534A (zh) * 2021-05-06 2024-05-10 细胞基因公司 使用n-((r)-1-(3-氯吡啶-2-基)-2,2,2-三氟乙基)-2-((s)-2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-甲酰胺的治疗方法
CA3246654A1 (en) * 2022-03-24 2023-09-28 Antares Therapeutics, Inc. METHODS FOR SYNTHESIZING EGFR INHIBITORS
US20250282795A1 (en) * 2022-04-20 2025-09-11 Celyn Therapeutics, Inc. EGFR Inhibitors in cancer treatment
WO2026047022A1 (en) 2024-08-28 2026-03-05 Bayer Aktiengesellschaft Stable solid pharmaceutical dosage form comprising crystalline form of her2/mutegfr inhibitor and process for its preparation
WO2026047020A1 (en) 2024-08-28 2026-03-05 Bayer Aktiengesellschaft Crystalline forms of her2/mutegfr inhibitors and process for their preparation
CN119264091B (zh) * 2024-09-04 2025-05-27 康龙化成手性医药技术(宁波)有限公司 一种1,5-双取代-3-氧杂双环[3.1.1]庚烷的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US7211573B2 (en) 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
DE102006033140A1 (de) 2006-07-18 2008-01-24 Merck Patent Gmbh Aminoindazolharnstoffderivate
BRPI0810498A2 (pt) 2007-04-27 2014-10-14 Sumitomo Chemical Compay Ltd Composto amida e seu uso
ES2424977T3 (es) 2007-08-08 2013-10-10 Glaxosmithkline Intellectual Property Development Limited Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
US8546413B2 (en) * 2009-06-15 2013-10-01 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP3033342A1 (en) 2013-08-13 2016-06-22 Grünenthal GmbH Annelated pyrroles and their use as crac inhibitors
JP6468611B2 (ja) * 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
EP3157914B1 (en) 2014-06-17 2018-09-26 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CA2969771A1 (en) 2014-12-08 2016-06-16 Bayer Pharma Aktiengesellschaft Novel aryl-cyanoguanidine compounds
US10301306B2 (en) 2014-12-15 2019-05-28 Bristol-Myers Squibb Company Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors
TN2017000329A1 (en) * 2015-01-28 2019-01-16 Bayer Pharma AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
EP3700904B1 (en) * 2017-10-24 2023-07-19 Bayer AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives

Similar Documents

Publication Publication Date Title
JP2022532850A5 (https=)
FI3959211T3 (fi) 4h-pyrrolo[3,2-c]pyridin-4-oniyhdisteitä
JP7493251B2 (ja) ピラゾール置換縮合環誘導体並びにその製造方法及び応用
JP2019510746A5 (https=)
CN103402519B (zh) 肿瘤治疗剂
JP2024527567A5 (https=)
JP7732668B2 (ja) 窒素含有多環式縮合環系化合物、その薬学的組成物、製造方法及び用途
JP2023536164A5 (https=)
JP2022536728A5 (https=)
JP7394768B2 (ja) キナーゼ阻害剤としての環状イミノピリミジン誘導体
JP7227913B2 (ja) 血液悪性腫瘍患者の治療方法
JP2016525076A5 (https=)
JP2016526540A5 (https=)
JP2005534669A5 (https=)
NZ603654A (en) Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
KR20170049604A (ko) Bub1 억제제로서의 벤질 치환된 인다졸
JP2016525509A5 (https=)
JP2017505790A5 (https=)
JP2020514292A (ja) 癌の治療に対する併用療法
WO2010031265A1 (zh) 用于治疗增生性疾病的药物组合物
JP2009504771A5 (https=)
WO2019045036A1 (ja) エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤
CN106255500B (zh) 用于治疗癌症的新的头孢菌素衍生物
JP6908287B2 (ja) 脳腫瘍の処置のための治療剤としての２−アミノピリミジン誘導体
JP2023550902A5 (https=)